Acrux Gains FDA Approval and Raises $2.65 Million

Acrux Limited (AU:ACR) has released an update.

Acrux Limited has announced the U.S. FDA approval of its Nitroglycerin Ointment, alongside securing $2.65 million through a share placement to institutional investors. This development, coupled with a share purchase plan for eligible shareholders, highlights Acrux’s strategic efforts in expanding its footprint in the pharmaceutical market.

For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.